Intracranial Dural Arteriovenous Fistulas: Classification, Imaging Findings, and Treatment

D. Gandhi, J. Chen, M. Pearl, J. Huang, J.J. Gemmete and S. Kathuria

AJNR Am J Neuroradiol published online 12 January 2012
http://www.ajnr.org/content/early/2012/01/19/ajnr.A2798
Intracranial DAVFs are pathologic shunts between dural arteries and dural venous sinuses, meningeal veins, or cortical veins. DAVFs account for 10%–15% of intracranial arteriovenous malformations. DAVFs are distinguished from parenchymal or pial arteriovenous malformations by the presence of a dural arterial supply and the absence of a parenchymal nidus. Most DAVFs present in adulthood and are located in the transverse, sigmoid, and cavernous sinuses. Pediatric DAVFs are predominantly idiopathic, though a small percentage of patients have a history of previous craniotomy, trauma, or dural sinus thrombosis (Fig 1). Two etiologic hypotheses based around sinus thrombosis have been put forward. The first is that physiologic arteriovenous shunts between meningeal arteries and dural venous sinuses enlarge in response to elevated local venous pressure, resulting in a pathologic shunt. The second is that venous hypertension due to outflow obstruction causes decreased cerebral perfusion and promotes neoangiogenesis. Heritable risk factors for venous thrombosis, such as antithrombin, protein C, and protein S deficiencies, have furthermore been associated with DAVF occurrence. These findings implicate the role of an underlying hypercoagulability in the development of DAVFs. The etiology of pediatric DAVFs is thought to be congenital or a result of birth trauma, infection, or maternal hormones.

Classification and Natural History

The DAVF venous drainage pattern determines the severity of symptoms and provides the foundation for the classification schemes (Tables 1 and 2) of Borden et al. Both of these systems associate CVD with increased risk of intracranial hemorrhage and nonhemorrhagic neurologic deficits.

The Borden classification system stratifies lesions on the basis of the site of venous drainage and the presence or absence of CVD (Fig 2). Borden type I lesions have the direct communication of meningeal arteries with a meningeal vein or dural sinus and exhibit normal antegrade flow. Type II lesions have shunts between the meningeal arteries and dural sinus, with retrograde flow into the subarachnoid veins, causing venous hypertension. Type III lesions have direct drainage of meningeal arteries into subarachnoid veins or an “isolated” sinus segment. The latter phenomenon is the result of thrombosis on either side of the arterialized sinus segment, which directs retrograde flow into the subarachnoid venous system. The Borden classification scheme further subclassifies lesions as single-hole (a) or multiple-hole (b) fistulas.

The Cognard classification is based on the direction of dural sinus drainage, the presence or absence of CVD, and venous outflow architecture (nongeniculate cortical veins, ectasia cortical veins, or spinal perimedullary veins). Type I lesions drain into the dural sinus, have an antegrade flow direction, and lack CVD. Type II lesions are subdivided into three subcategories: type Ia lesions drain retrogradely into a dural sinus without CVD, type Ib lesions drain antegrade into a dural sinus with CVD, and type Ia + b lesions drain retrogradely into a dural sinus with CVD. Types III, IV, and V lesions all have CVD, absent dural venous drainage, and varying cortical venous outflow architecture.

Lack of CVD (Borden type I, Cognard types I, Iia) is a favorable feature and is associated with a benign natural history. These patients typically present incidentally or with...
symptoms of increased dural venous drainage (eg, pulsatile tinnitus, exophthalmos). The risk of intracranial hemorrhage from Borden type I (Cognard types I, IIa) lesions is extremely low.\textsuperscript{16,18} In either classification scheme, the presence of CVD (Borden type II and III, Cognard types IIb-V) is an aggressive feature that places DAVFs in a higher risk category. In these lesions, an annual mortality rate of 10.4%, an annual risk of intracranial hemorrhage of 8.1%, and annual risk of NHND of 6.9% have been reported.\textsuperscript{14,19} Subdividing lesions with CVD (Borden types II and III, Cognard types IIb-V) into symptomatic and asymptomatic types may further improve the accuracy of risk stratification.\textsuperscript{18} Zipfel et al\textsuperscript{18} demonstrated a significant difference in the risk of annual hemorrhage between symptomatic and asymptomatic types: 7.4% versus 1.5%, respectively.

Although classifying DAVFs is helpful for risk stratification, one should be aware that these lesions have a dynamic nature. Type I lesions can develop CVD with time due to the development of venous stenosis, venous thrombosis, or increased arterial flow.\textsuperscript{19,20} The risk of conversion is low, having only been reported in 2% of low-grade lesions.\textsuperscript{19} Cases of spontaneous thrombosis/resolution of DAVFs have also been reported.\textsuperscript{21-27} Any change in a patient’s symptoms can reflect exacerbations of the venous drainage pattern and prompt further imaging work-up.

### Clinical Presentation

A majority of patients with DAVFs present in the fifth and sixth decades with symptoms related to lesion location and pattern of venous drainage.\textsuperscript{28} Pulsatile tinnitus is a common symptom that results from increased blood flow through the dural venous sinuses, particularly in relation to transverse and sigmoid sinus lesions.\textsuperscript{13,18,19} Cavernous sinus DAVFs can present with ophthalmoplegia, proptosis, chemosis, retro-orbital pain, or decreased visual acuity.\textsuperscript{4,12,14}

Severe presentations include intracranial hemorrhage and nonhemorrhagic neurologic deficits such as seizures, parkinsonism, cerebellar symptoms, apathy, failure to thrive, and cranial nerve abnormalities, including rare cases of trigeminal neuralgia.\textsuperscript{28-33} Some symptoms, including dementia and cognitive decline, may improve after treatment.\textsuperscript{34} Hemorrhagic presentations are more frequent in high-grade (Borden types II and III, Cognard types IIb to IV) DAVFs. Unexplained subarachnoid or lobar hemorrhages should prompt consideration of a DAVF in the differential diagnosis.

### Diagnosis

Initial radiologic evaluation includes CT and MR imaging. Noncontrast CT is limited to identifying intracranial hemorrhage and edema due to venous congestion. MR imaging is
more helpful because it can demonstrate dilated vessels, venous pouches, vascular enhancement, and signs of venous hypertension in high-grade lesions (e.g., white matter hyperintensity, intracranial hemorrhage, or venous infarction). These findings, however, vary with the type of DAVF investigated. Type I and II lesions may reveal flow-void clustering, engorged ophthalmic veins, or proptosis, whereas aggressive type II or III lesions are more likely to show dilated vessels, prominent vascular enhancement,1 and hemorrhage.

Any suspicious flow void cluster around the dural venous sinus should prompt additional evaluation with dynamic CTA, MRA, or DSA.1 CTA is particularly useful in treatment planning by precisely defining the arteriovenous shunt relative to surrounding brain and skull anatomy. Recent publications on 4D CTA by using 320-section multidetector row CT angiography have highlighted its potential to correctly diagnose, classify, and assist treatment planning for DAVFs (Fig 1).35,36 Studies have reported, however, that CTA has reduced sensitivity versus MRA for the detection of DAVFs (15.4% versus 50%).37 Time-resolved MRA techniques are also promising and may be reliable for DAVF screening and surveillance in the future.38,39 Due to current limitations of low resolution, restricted FOV, and saturation artifacts, the negative predictive value of MRA is inadequate to exclude DAVFs.40

Conventional angiography remains the most accurate method for detection and classification of DAVFs.15 The adjunct of FDCT to angiography is yielding previously unachievable high-resolution anatomic detail. Groups have demonstrated the utility of FPCT to precisely delineate the fistula site and provide superior visualization of arterial feeders and venous outflow.41,42

**Treatment**

Endovascular approaches have become the mainstay of DAVF therapy, but the optimal approach for each case should involve discussions among a multidisciplinary team of interventional neuroradiologists, neurosurgeons, neurologists, and radiation oncologists. Careful assessment of a patient’s clinical presentation, current status (age, medical condition, comorbidities), and type of lesion (location, classification, and angiographic features) should be conducted before embarking on any treatment.

The risk of treatment should always be weighed against the natural history and expected clinical course of the lesion. High-grade lesions should be treated early to avoid the risks of hemorrhage and NHND. Conservative treatment is generally indicated in patients with low-grade fistulas (Borden I; Cognard I, IIa). Close follow-up is necessary to assess the development of new symptoms or progression of existing ones. Low-grade lesions with severe debilitating symptoms (e.g., severe tinnitus or visual symptoms resulting in poor quality of life) are, however, candidates for prompt endovascular repair.

**Endovascular Therapy**

During the past 2 decades, embolization by using transarterial, transvenous, or, occasionally, combined approaches has become a first-line treatment for DAVFs. Treatment is aimed at complete elimination of the arteriovenous shunt—incomplete treatment allows recruitment of collateral vessels and persistent risk of hemorrhage. When complete occlusion of the shunt is not feasible or considered too risky, selective disconnection of CVD should be considered. This approach can have an efficacy comparable with DAVF obliteration in preventing neurologic morbidity with lower levels of procedural risk.43,44

The optimal method of endovascular treatment remains debated and controversial. A consideration of the advantages and disadvantages of transarterial, transvenous, and combined approaches should be given in each case before proceeding with embolization.
A vast majority of DAVFs lends themselves to treatment via a transarterial approach. In cases in which the fistula site involves a highly stenotic, compartmentalized, or isolated sinus or a relatively small and tortuous cortical vein, TAE may be the only option because a transvenous option is difficult or impossible (Fig 3).

TAE involves superselective distal catheterization of arterial feeders. Ideally, the microcatheter tip should be “wedged” in the feeding artery and the embolic agent should penetrate the fistulous connection and proximal aspect of the venous receptacle. Available embolic agents include particles, coils, ethanol, n-BCA glue, and Onyx (ev3, Irvine, California). Particles should generally be avoided because complete durable fistula obliteration is usually impossible, allowing subsequent recanalization from collateral recruitment. Coils can be used as an adjunct to liquid embolic agents to reduce the rate of shunt surgery in high-flow lesions but are not usually curative when used alone.

n-BCA has been extensively used for TAE during the past 3 decades. It is injected in liquid form and solidifies on contact with ionic solutions such as blood, resulting in occlusion of the desired vascular bed. The injection duration needs to be fairly short, and an experienced operator is essential. The thrombogenic properties of n-BCA can promote progressive occlusion of residual shunt flow seen on immediate posttreatment angiography. Several studies have demonstrated excellent cure rates by using n-BCA for TAE. However, multiple procedures are often necessary, and >1 treatment approach can be required (eg, transvenous, transarterial therapy, and/or operative resection) for complex lesions. Caution should be exercised to avoid accidental embolization of the distal venous system. This complication may result in progressive venous occlusion, exacerbation of venous hypertension, and/or venous infarction.

The use of Onyx has been increasingly reported for the treatment of DAVFs. This nonadhesive embolic agent consists of ethylene-vinyl alcohol copolymer dissolved in various concentrations of DMSO with micronized tantalum powder for radiopacity. On contact with blood, DMSO rapidly diffuses from the mixture, causing in situ precipitation of the polymer without adhesion to the vascular wall. The polymer initially precipitates within the peripheral area of the blood vessel, with secondary occlusion of the central vessel. This allows a longer more controlled injection with better penetration of the vascular bed compared with n-BCA. The operator also has the option of stopping the injection if Onyx begins to track toward another arterial pedicle, venous outflow vessel, or suspected dangerous anastomoses. The injection can then be restarted after several seconds because Onyx...
will track toward the low-pressure environment of the residual fistula. Another technical advantage of Onyx is the possibility of obtaining control angiograms during the embolization. This allows assessment of the remaining fistula flow and the changing hemodynamic pattern of a complex lesion. A major advantage of Onyx is the ability to cure complex multifidder fistulas via a single pedicle (Fig 3). \(^{49}\) Excellent cure rates have been reported with this agent, with a high proportion of treatments completed in a single session. \(^{41,45,52}\) In a series of 30 patients with DAVFs with CVR, Cognard et al\(^{45}\) achieved a complete cure in 24 patients. Of these 24 patients, 20 cures were achieved after a single procedure.

The use of Onyx is associated with some disadvantages as well. Prolonged fluoroscopic times can occur, and careful attention must be paid to avoid radiation-induced injury. \(^{41,52}\) Other reported events including catheter entrapment, angio-toxicity from DMSO, and cranial nerve injury. \(^{41,46}\) Many of these complications can be prevented if the operators recognize their potential mechanisms. DMSO-induced angioxicity and vasospasm can be prevented by slow Onyx injection. \(^{41}\) Similarly, catheter retention can be avoided by limiting reflux around the catheter tip and positioning the catheter tip in a relatively straight vessel segment. We avoid Onyx injection into vessels known to supply the lower cranial nerves (petrosal branch of the middle meningeal artery, stylomastoid branch of the posterior auricular and occipital arteries, and jugular branch of the ascending pharyngeal artery). Under these circumstances, alternative suitable vessels for embolization can usually be found. If adequate penetration into the fistula is achieved, the remaining feeders will thrombose spontaneously.

**TVE**

TVE is performed by retrograde catheterization of the involved dural sinus or cortical vein followed by deposition of coils and/or liquid embolic agents adjacent to the shunt. The aim of this treatment is occlusion of the arteriovenous fistula and/or disconnection of leptomeningeal or cortical reflux with preservation of normal venous drainage. TVE is more safely used when the diseased sinus segment has minimal contributions to normal venous outflow and can be completely occluded. More caution is required when the dural venous sinus maintains drainage of normal veins—in these circumstances, precise identification of the fistula is essential to avoid potential venous infarction or hemorrhage. Partial embolization of the involved dural sinus should be avoided because the diversion of shunt flow into the normal cerebral venous pathways can lead to worsening CVD.

Benefits of TVE include the relative simplicity of retrograde access to the fistulous site and the ability to close the fistula in 1 session. TVE is particularly advantageous for DAVFs with multiple arterial feeders of small size or tortuous course for which complete or practical treatment by TAE is not feasible. \(^{45,54}\) Lesions of the cavernous (Fig 4) and transverse/sigmoid sinuses are more optimal for TVE than those involving the superior sagittal sinus. \(^{53}\) The rates of complete angiographic fistula ablation by TVE have been reported at 71%–87.5%. \(^{53-55}\)

The risks of TVE include vessel perforation, infarction, intracranial hemorrhage, and transient or permanent neurologic deficits related to changes in venous drainage course. \(^{53,56}\) Transient ophthalmoplegia has been reported in 14% of cavernous sinus embolizations, \(^{59}\) but patients typically have a full recovery. The risk of cranial nerve damage from coil mass effect or direct coil injury can be avoided through the use of liquid embolic agents. Permanent complications have been reported in 4%–7% of cases. \(^{53-55}\) Despite these risks, TVE can be a safe and effective procedure for many DAVFs and can be used as an adjunct to TAE for a complete cure.

**Surgery**

Due to the efficacy of endovascular treatment, surgery is currently indicated in cases in which endovascular approaches have failed or are not feasible. A variety of options is available, including direct intraoperative embolization of meningeal arteries or veins, resection of abnormal dura, packing of the diseased sinus, disconnection of the retrograde leptomeningeal venous drainage, and skeletonization of the dural sinus with disconnection of the dural arterial supply (Fig 5). Certain anatomic locations of DAVFs are more amenable for surgery. These include the floor of the anterior cranial fossa and the superior sagittal sinus, where arterial access is difficult and/or sacrifice of the sinus is often undesirable. \(^{57,58}\) DAVFs that involve eloquent feeders are also better addressed by using a surgical or combined approach to ensure vessel preservation.
Presurgical arterial embolization can reduce the risk of surgical complications. The efficacy of this combined approach for DAVF ablation has been reported at nearly 100%, but the risk of morbidity and mortality remains considerable at >10%.57,59,60

SRS

Studies of SRS for DAVFs remain preliminary and have primarily involved low-risk lesions or those that are not amenable to endovascular or surgical approaches. Lesions are irradiated with 20–30 Gy, which causes vessel thrombosis and fistula closure during a latency period ranging from several months to a year. Until completion of vessel thrombosis, the hemorrhage risk remains elevated,62 so SRS is inappropriate as the primary treatment in DAVFs with CVD. Early results have been encouraging, with obliteration rates as high as 93% for combined endovascular embolization and SRS62 but have also demonstrated rates as low as 50% when only SRS is used.63 There have also been significant disparities in efficacy depending on the location of the fistula,64 reflecting challenges for shunt targeting in complex lesions. Experience with SRS currently remains limited, and this technique should be reserved for carefully selected DAVFs for which endovascular and surgical options have been exhausted.

Conclusions

A number of classification schemes have been devised to aid in the clinical management of DAVFs. The Borden classification stratifies the lesions into 3 types according to the venous drainage pattern (dural venous sinus [types I and II] versus cortical vein [type III] and the presence [types II and III] of cortical venous reflux. These classifications are useful for categorizing lesions as benign or aggressive, but they do not consider the natural history of these lesions. DAVFs are dynamic lesions that may either spontaneously regress or progress, so close attention to any change in symptoms is important because this may signify a change in the type of venous drainage pattern. Additionally, further subdivision of the DAVFs with CVD into symptomatic and asymptomatic lesions may help stratify high-risk patients and modify treatment planning in the future. Noninvasive imaging evaluation by CTA and MRA can provide useful information for diagnosis, classification, and treatment planning, but the criterion standard for DAVF imaging remains DSA, particularly with the new adjunct of conebeam CT. Treatment should be pursued for all DAVFs with CVD or intolerable symptoms, and management decisions should be approached by a multidisciplinary team that is capable of evaluating all possible therapies.

Acknowledgments

We thank Lydia Gregg, Medical Illustrator and Research Associate, Division of Interventional Neuroradiology, Johns Hopkins School of Medicine, for her contribution with Fig 2.


References

29. Lucas Cde P, Zabramski JM.
24. Landman JA, Braun IF.
22. Endo S, Koshu K, Suzuki J.
8. Kerber CW, Newton TH.

venous fistulas: the pathologic findings of venous hypertensive encephalopathy caused by cranial dural arteriovenous fistulae: report of three cases and review of the literature.

J Neurosurg 1995;85:830–37

Clinical course of cranial dural arteriovenous fistulas: outcome of conservative management based on the natural history of the lesion. J Neurosurg 2002;97:767–70


The macro and microvasculature of the dura mater.

Laryngoscope 1993;33:5–8


